Street J A, Walsh A
Eur J Pharmacol. 1984 Jul 13;102(2):315-24. doi: 10.1016/0014-2999(84)90263-2.
Ten beta-adrenoceptor blocking drugs varying in lipophilicity and beta-adrenoceptor blocking potency were examined for inhibitory effects on synaptosomal [3H]noradrenaline uptake. All compounds produced a concentration-dependent inhibition of noradrenaline uptake, but were at least one order of magnitude less potent than desmethylimipramine and cocaine. The order of potency was pronethalol greater than propranolol greater than betaxolol greater than alprenolol greater than oxprenolol greater than practolol greater than metoprolol greater than acebutolol greater than sotalol greater than atenolol, with IC50 values ranging from 4.0 X 10(-6) to 2.2 X 10(-3) M. Uptake inhibition was unrelated to beta-adrenoceptor blocking potency, but was highly correlated with drug lipophilicity. (+)-Propranolol was an effective uptake inhibitor, as was the local anaesthetic procaine. Kinetic analysis of uptake inhibition by propranolol, oxprenolol, metoprolol and procaine revealed a mixed inhibition for all four agents examined. It is suggested that this effect of beta-adrenoceptor blockers may be mediated, at least in part, by an action on membrane phospholipids associated with the noradrenaline carrier protein, and that noradrenaline uptake inhibition may underlie certain central side-effects observed with some drugs in this group.
研究了10种亲脂性和β-肾上腺素能受体阻断效能各异的β-肾上腺素能受体阻断药物对突触体[3H]去甲肾上腺素摄取的抑制作用。所有化合物均产生浓度依赖性的去甲肾上腺素摄取抑制作用,但效力至少比去甲替林和可卡因低一个数量级。效力顺序为:丙萘洛尔>普萘洛尔>倍他洛尔>阿普洛尔>氧烯洛尔>普拉洛尔>美托洛尔>醋丁洛尔>索他洛尔>阿替洛尔,IC50值范围为4.0×10(-6)至2.2×10(-3)M。摄取抑制与β-肾上腺素能受体阻断效能无关,但与药物亲脂性高度相关。(+)-普萘洛尔是一种有效的摄取抑制剂,局部麻醉药普鲁卡因也是如此。对普萘洛尔、氧烯洛尔、美托洛尔和普鲁卡因摄取抑制的动力学分析显示,所研究的所有四种药物均为混合抑制。提示β-肾上腺素能受体阻断剂的这种作用可能至少部分是通过作用于与去甲肾上腺素载体蛋白相关的膜磷脂介导的,而去甲肾上腺素摄取抑制可能是该组中某些药物所观察到的某些中枢副作用的基础。